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ABSTRACT
Background:
Each year in the U.S., an estimated minimum of 40,000 infants are
expected to be affected with some form of congenital heart defect (CHD), while a
quarter of infants affected with CHD will require invasive treatment within the first
year1. The current treatments for CHD that involve valve intervention are not
tailored to growing children. Mechanical and biological substitute of valves
deteriorate and accumulate calcification when implanted in very young patients2.
In addition, children with current valve substitutes are faced with a lifetime of drug
regimens, such as anti-coagulants, to prolong the longevity of the replacements
and multiple surgeries for valve implantation3.
Long-term goal:
Our overarching aim is to create a tissue engineered pulmonary valve
(TEPV) as a living replacement, which addresses the short comings of current
treatments. A TEPV approach for children with CHD would create a living
scaffold with the potential of integrating into its environment, regenerating,
adapting, and growing in parallel with the somatic growth of the child. This will
alleviate the need for any additional surgeries throughout their life.
Approach:
To achieve the goal of creating a living TEPV, we proposed combining
non-immunogenic valve scaffolds and autologous endothelial cells obtained from
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human adipose derived stem cells (hADSCs) by in vitro differentiation. This is
only a first step in our larger project to seed the valve interstitium with autologous
fibroblasts and the external surfaces with endothelial cells (ECs). The acellular
scaffolds were obtained via decellularization of porcine pulmonary valves using a
pressurized perfusion system. Biochemical assays and histology tests validated
decellularization completeness and bioreactor studies confirmed valve
hemodynamics. hADSCs were differentiated in vitro towards ECs using added
growth factors and dynamic shear conditioning. After propagation, to optimize
cell seeding on both surfaces of the valve scaffolds (atrial and ventricular), we
used fibrin gel as a delivery vehicle and compared manual seeding with 3D
bioprinting as a means of EC seeding and evaluated cell retention and viability
using Live/Dead assays. After seeding, we exposed the seeded valves to
physiological environments of pulmonary flow and pressures within a valve
bioreactor for conditioning and maturation of the endothelium.
Results
Our data show complete pulmonary valve decellularization in our system,
including the sinus and the ascending pulmonary artery, efficient differentiation of
hADSCs into ECs using growth factors and shear, improved seeding using the
3D bioprinter and adequate coverage of ECs on both surfaces of the valves after
bioreactor conditioning. This initial success opens possibilities for complete cell
repopulation in vitro with autologous cells before implantation.
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PART 1: BACKGROUND INFORMATION AND PROJECT
RATIONALE

1

CHAPTER 1: BACKGROUND INFORMATION

2

1: ANATOMY AND PHYSIOLOGY
1.1: HEART AND CIRCULATION
A normal healthy heart is a muscular organ that sits inside the chest, and
is composed of four valves, two atriums and two ventricles. The purpose of the
heart is twofold, to push oxygenated blood to the extremities and to push
deoxygenated blood into the lungs.

FIGURE 1: Normal heart and normal heart flow. Adapted by Margarita Portilla from CDC and
Prevention (2020).
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A normal heart’s anatomy is shown in FIGURE 14, where the blue shaded
regions show the path of deoxygenated blood (blue arrow) and the red shaded
region shows the path of oxygenated blood (red arrow). The heart is a large
pump which expels bursts of blood to the circulatory system. The heart is
compartmentalized as the right and left side, where an atrium and a ventricle
reside. The right and left side are separated by a septum which allows blood that
is (left) oxygenated or (right) deoxygenated to be separate. The atria are
considered primer pumps2 for the ventricles, specifically holding residual blood
within while the ventricle is either contracting or relaxing. The ventricles are
considered the main pumps due to the larger volume of blood they can hold, and
the force which the right or left ventricle propels blood into the lungs or the rest of
the body, respectively.
Blood circulates throughout the heart following the cardiac cycle, which
consists of a period of relaxation/contraction, diastole/systole. During diastole,
the heart fills with blood followed by systole, where blood moves through its
respective path. In addition, during the cardiac cycle pressure gradients occur as
blood is compartmentalized as the valves close.
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B

FIGURE 2: Blood flow patterns. A) Circulation within the heart. B) Path of blood
circulation throughout the body and locations where gas exchange occurs. Images from
Guyton & Hall’s Medical.

The deoxygenated blood from the trunk and lower extremities come into
the right side of the heart into the right atrium through the inferior vena cava,
while the deoxygenated blood from the head and upper extremities comes in
from the superior vena cava (FIGURE 2: A5).
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FIGURE 3: Cross-sectional image of heart, all heart valves are visible. Image by OpenStax,
Houston, Texas, 2020– Anatomy & Physiology

The atrioventricular valves (A-V valves, shown in FIGURE 36 as the
tricuspid and mitral valve) are located between the atria and the ventricle,
prevent backflow from the ventricle; while the semilunar valves (Shown in
FIGURE 3, as the aortic and pulmonary valves) prevent back flow from the aortic
and pulmonary arteries into the ventricles during diastole. Both right and left
heart pump in parallel where the ventricles fill passively, then the atrium then
contract near the end of ventricular diastole, any residual blood in the atrium is
forced into the ventricle during the contraction and the A-V valves close. The
closure of the valves is due to increasing pressure in the ventricles as they start
to contract. As the ventricles contract, pressure within reaches a threshold which
opens the semilunar valves. As blood is ejected through the semilunar valves,
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the pressure within the ventricle is relieved and the semilunar valves and the A-V
valves open to start the cycle again7. Finally, the blood from both sides of the
heart follow their respective paths to meet at locations where there is gas
exchange such as capillaries, kidneys, gastrointestinal tract, and the lungs
(FIGURE 2: B5).
Valve closures occur passively according to the pressure gradient over the
valve. Closure of the valve occurs when the backward pressure gradient causes
the blood to flow in a backward direction; opening of the valves occurs when the
forward pressure gradient causes the blood to flow in the forward direction.
The focus of the rest of the literature will be on the pulmonary valve which
is paramount in the circulation of the blood as it is the valve which leads to the
conduit for the lungs to oxygenate the blood.

1.1.1: FETAL HEART DEVELOPMENT AND FETO-NATAL
CARDIOVASCULAR TRANSITION
Many changes can arise during the development of the heart; thus, it is
important to understand its development from gestation to birth. The heart arises
from the mesoderm, one of the three primary germ layers, and is the first
functional layer to form after fertilization.
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FIGURE 4: Progression of Embryonic Heart Development. Image by: OpenStax, Houston,
Texas, 2020– Anatomy & Physiology

During embryonic development (around day 21 or 22 of fertilization)8, the
heart bulge is seen on the anterior surface of the embryo, known as the
cardiogenic area (Top left, FIGURE 4). Receiving signals from the endoderm, the
cardiogenic area forms two strands called the cardiogenic cords. As the cords
develop, the lumen develops with in. At this point, they are referred to as
endocardial tubes, at 20 days (FIGURE 4). The endocardial tubes fuse together
to form a primitive heart tube (21 days, FIGURE 4), where five distinct regions
are formed, from head to tail: truncus arteriosus, bulbus cordis, primitive
ventricle, primitive atrium, and sinus venosus. At this point all venous blood flows
into the sinus venosus, and contractions propel the blood from tail to head, or
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from sinus venosus to truncus arteriosus. Further progression occurs where the
chambers of the heart are developed (Bottom row, FIGURE 4).

FIGURE 5: Fetal Circulation. Image by Stanford Children’s Health, 2020.

Information from the National Health Services in the United Kingdom
indicates the fetal heart is fully developed at 10 weeks9. Even though the organ
in fully formed, the blood circulation is not yet like an adult, depicted in FIGURE
5. Oxygenated blood and nutrients flow into the unborn baby from the umbilical
cord. The enriched blood flows through the umbilical vein towards the fetus’s liver
and moves through the ductus venosus, a shunt. As the blood flows through the
shunt, some blood stays in the liver while most flows through a large vessel, the
inferior vena cava, into the right atrium of the heart. Once the enriched blood is in
the heart, most of it flows through the foramen ovale, another shunt, into the left
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atrium. From the left atrium, the blood flows into the left ventricle and then it is
pumped through the ascending aorta where the blood is dispersed to the brain,
the heart muscle, and to the lower body. In contrast, the blood that returns from
the fetal body, containing carbon dioxide and waste products, enters the right
atrium and flows into the right ventricle. As an adult, the blood at this stage would
go to the lungs, but instead the fetal venous blood bypasses the lungs and flows
through the ductus arteriosus into the descending aorta, which connects to the
umbilical vein. Carbon dioxide and waste products in the blood are exchanged
for oxygen and nutrient enriched blood through the placenta, where the cycle
begins again.
At the point of birth, the newborn goes through drastic changes as they
take their first breath. As the newborn’s umbilical cord is clamped, seizing the
avenue of blood supplied by their mother, the lungs expand, and the ductus
arteriosus, ductus venosus, and foramen ovale close. At this point, the infants
blood circulation is the same as an adult. Further discussed, will be the anatomy
of the heart valve anatomy and physiology.

1.2: HEART VALVE ANATOMY AND PHYSIOLOGY
1.2.1: STRUCTURE
For many years, heart valves have been assumed to be passive
participants during the cardiac cycle. Many believed that only due to changes in
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transvalvular pressure and myocardial reaction, heart valves opened and
closed10. The heart has four valves, grouped into the A-V valves and semilunar
valves. The focus of this dissertation are semilunar valves which need to be
analyzed and understood further for the advancement of this dissertation. The
aortic valve and pulmonary valves have many commonalities due to their similar
roles in the heart, especially their placement which induces pressure on both.
The Center for Disease Control states that valvular heart disease deaths are
more commonly attributed to aortic valve disease11, thus it has been studied
more than the pulmonary valve. The aortic valve is consistently exposed to
increased pressures in comparison to the pulmonary valve. The pulmonary valve
is situated between the right outflow tract of the heart which leads to the lungs,
and the right ventricle12 and is comparable in design to the aortic valve. One of
the purposes of the pulmonary valve is to prevent any backflow into the right
ventricle.
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FIGURE 6: Illustration of the pulmonary valve. Top: Cross Sectional view of the valve, with the
pulmonary artery above and right ventricle below. Bottom: Pulmonary valve transected between
the right and left leaflet. Image adapted by Margarita Bruce from Shatarat, A. “Two
17
atrioventricular valves Two semilunar valves.” 2008 .

In FIGURE 613 the macro-structure of the pulmonary valve is depicted, as
a transactional view of the pulmonary artery in the middle the pulmonary valve at
the top of the image and an open view at the bottom of the figure. In the
transactional view of FIGURE 6, the pulmonary valve can be seen in its
anatomical placement, where the top is the pulmonary artery which then leads to
the lungs and the bottom is the right ventricle. The point which the three leaflets
meet is called the nodule. Each leaflet is a thin membrane and is referred to their
anatomical position in the heart, which are the anterior, left, and right leaflet.
12

Behind each leaflet is their respective sinus, and the point which they meet is
called the commissure; one commissure connects the right leaflet with the
anterior leaflet, another connects the anterior leaflet with the left leaflet, and
finally the last one connects the left leaflet with the right leaflet. At the top of each
sinus, there is a circular ring called the sinotubular junction which is composed of
a muscular ring that defines where the pulmonary valve sits inside the artery. In
comparison to the aortic valve, the pulmonary leaflets are thinner and the noduli
are smaller than their valvular counterpart12. The pulmonary leaftlets consist of
the hinge, the belly, and the coapting surface and the lanulla with the noduli of
Aranti12.

FIGURE 7: Pulmonary valve with layers identified as (TOP) fibrosa, (MIDDLE) spongiosa, and
(BOTTOM) ventricularis. Adapted by Margarita Bruce from Rocca, F.D. et al. (2000)18.

Microscopically, the pulmonary leaflets have the same three regions as
the aortic leaflets, which are the fibrosa (superior layer close to the pulmonary
artery), spongiosa, and the ventricularis (FIGURE 714). Unlike the aorta, these
layers are often thinner, especially the center layer of the spongiosa15. Under the
ventricular endothelium of the pulmonary valve is the lamina ventricularis which
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consists of a tight network of retricular fibers with sparce collagenous and elastic
fibers. Following the ventricular lamina, present is the lamina radialis which is
composed of radial oriented collagenous and elastic fibers with space reticular
fibers. This layer is then proceeding into the endocardium and the
subendocardial layer of the ventricle12. Furthermore, the microscopic
environment of the pulmonary valve is dictated by the cellular components of
each region of the valve, such as endothelial cells and interstitial cells.

1.2.2: CELLULAR ANATOMY
1.2.2.1: VALVULAR ENDOTHELIAL CELLS
As per Chester, A.H. et al 10 heart valves have initially been referred to as
passive structures, but with much further investigation the living components of
the valves have led to the reconsideration of the valves dynamic role. Cellular
components, such as the endothelial cells, have demonstrated the dynamic
constituents of the heart valves. The endothelium of the leaflets of valves have
shown a remarkable manner of adapting to shear stress, bending forces, loading
forces, and strain10,16. Unlike their vascular counter parts, valvular endothelial
cells are aligned perpendicular to flow patterns, which is observed regardless of
substrate structure10,17. In regards to vascular endothelial cells,
mechanotransduction pathways such as Rho-kinase, phosphatidylinositol-3kinase and calpain are induced by laminar flow; where as such pathways are not
required for cytoskeletal reorganization in valvular endothelial cells10. In addition,
14

valvular endothelial cells proliferation is higher than their vascular counterparts10.
The differences between the vascular and valvular endothelial cells demonstrate
a difference in roles the endothelium has regarding their environmental site.
Although it is believed that the endothelial cells both have similar physiological
roles, valvular endothelial do not act like their vascular counterparts.
Valvular endothelial cells express von Willebrand Factor (vWF) and tissue
factor in aid to regulate coagulation16,17, thus being non-thrombogenic unless
inflammatory cytokines and/or other related factors analogous to injury are
detected. In addition, due to the constant repeated flow changes, endothelial
denudation is resisted thus coagulative factors tend to not be released as easily
as their vascular kin. In addition, endothelial cells interpret and respond to agents
in blood, which could be coagulative factors, nutrients, and other molecular
stimulants. Although valvular endothelial cells have been determined to have
diffusion limits 250µm (within the range of small blood vessels) in hypoxic
environments angiogenesis would occur, but the valve leaflets little to no blood
vessels inside16-18. Another duty of endothelial cells is regulation of underlying
cells. For the valvular associated cells, the underlying cells are valvular interstitial
cells (VICs) which are more fibroblastic in nature16,19. Valvular endothelial cells
respond to vasoactive agents by alterations of calcium currents and production of
prostaglandins20
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FIGURE 8: Depiction of complexity of endothelium, as per processes and protein
expressions, such as (A) CD31 (also referred to as PECAM-1), (B) von Willebrand Factor
(vWF), and (C) endothelial nitric oxide synthase (eNOS). Adapted by Margarita Bruce from
“Special Report: The Complexity of Endothelial Cells: A review” by Fajardo, et al. 1989 24.

In Fajardo, et al’s21 review of the complex behavior of endothelial cells, they
follow afore mentioned behaviors such as interpretation of molecules and/or
signals from surrounding their environment, angiogenesis, tone regulation, and
special metabolic functions. It is important to consider the characterization of
endothelial cells properly, as they not only need to express proteins that identify
the cell as endothelial, but also function as one (FIGURE 8). In this regard, three
proteins are identified as endothelial cell characteristics, as well as one metabolic
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function which are CD31, vWF, eNOS, and uptake of acetylated-low density
lipoproteins, respectively21.
CD31, also referred to as PECAM-1, is a protein that helps identify cell to cell
communication between endothelial cells (Fig 8, A); vWF is a protein stored
within the cell cytoplasm and will be released if injury occurs to the cell thus
initiating a signal cascade of injury to the rest of the cells (Fig 8, B); and finally,
endothelial nitric oxide synthase (eNOS), an enzyme that reacts to shear stress
that then signals the underlying basal lamina to conduct tone regulation to cells
underneath of the endothelium layer (Fig 8, C)22. Endothelial cell’s complex
functions lead us to further examine their influence on other cells, such as
smooth muscle cells for vascular endothelium and valvular interstitial cells for
valvular endothelium.

1.2.2.2: VALVULAR INTERSTITIAL CELLS
Valvular interstitial cells (VICs) are a dynamic population of at least two
distinct cells, smooth muscle cells with α-smooth-actin expression, and
fibroblasts10,12. Interstitial cells can contract and remodel, creating an active
population of cells which respond to various changes in their environment16,
such as valvular endothelial cells19. Unlike smooth muscle cells, VICs are highly
dynamic producers of protein and glycoaminoglycans19.
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VICs are highly susceptible to changes, due to their own elevated dynamic
and dependency on valvular endothelial cells23, to abnormal mechanics from
their environment. To elaborate, any anomaly of the valvular environment affects
valvular endothelial cells, in turn, due to the endothelial cells’ function, VICs are
highly affected. Thus, the consideration of maintaining a normal valvular
environment is paramount to avoid any cascade of abnormalities to deter any
valve to become pathological. Cases of valve pathology are seen in congenital
heart defects where the valvular environment is disrupted due to a defect, thus
the need to mitigate the defects to reduce ultimate failure of the heart.

2: PATHOLOGY OF CONGENITAL HEART DEFECTS
2.1: STATISTICS OF DISEASE
Cardiovascular disease (CVD) is the prime cause of death globally24,
furthermore taking an estimated 17.9 million lives each year25 worldwide. It is
speculated that by 2030, 43.9% of the United States population will have some
form of CVD26. Under the umbrella of CVD, more than five millions of Americans
are diagnosed with heart valve disease (HVD) each year27,28,. Although most of
the population that suffers from HVD are the elderly, the population of growing
children cannot receive the same treatment as their older counterparts. In the
U.S., hospital costs for individuals with cardiovascular defects in 2013 were
about $6.1 billion, where critical congenital heart defect associated
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hospitalizations had the highest mean and median cost of the birth defect
categories considered ($79,011 and $29,886, respectively)29,30.
Events which may lead children to have heart valve defects at birth,
referred to as congenital heart defects (CHD), lead to extensive surgeries
throughout the infant’s life. The American Heart Association estimates that out of
1,000 births at least eight babies will have some sort of CHD in the United
States31,32.

2.2: CRITICAL HEART DEFECTS
About one in every four babies born with a heart defect has a critical CHD
(CCHD) , identified as heart defects that lead to low levels of oxygen in a newborn,
and will have an invasive intervention with in their first year of life30. The cost of
identifying a newborn with critical CHD has been estimated at $20,862 per
newborn detected12 and hospitalizations with critical CHD account for 26.7% of all
costs for CHD hospitalization29, where pediatric hospitalizations with CHDs
accounted for approximately $5.6 billion in hospital costs, representing 15.1% of
costs for all pediatric hospitalizations in 20094.
CHD can be diagnosed during pregnancy using a special type of ultrasound,
called a fetal echocardiogram, which creates pictures of the heart of the developing
baby. If the defects are not able to be identified during the pregnancy, they can be
identified at birth or as the child ages. Low levels of oxygen detected with pulse
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oximetry are the primary identification of a potential CCHD, such as pulmonary
atresia (FIGURE 9: A4), hypoplastic left heart syndrome (FIGURE 9: B30),
coarctation of the aorta (FIGURE 9: C33) and Tetralogy of Fallot (FIGURE 9: D34),
detected.
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FIGURE 9: Examples of Congenital Heart Defects. A. Pulmonary Atresia defect- the
pulmonary valve does not form; box identifies the defect. B. Hypoplastic Left Heart
Syndrome- The left sideof heart does not form correctly; box identifies the defect. Potential
structures effected are the left ventricle, the mitral valves, the aortic valve, the ascending
aorta, and the atrial septum. C. Coarctation of the Aorta- The aorta is narrowerthan usual.
D. Tetralogy of Fallot- Birth defect that affects normal blood flow through the heart, usually
made up of fourdefects. 1) A ventricular septal defect, 2) Narrowing of pulmonary valve and
main pulmonary artery, also known as pulmonary stenosis. 3) Aortic valve is enlarged and
due to the ventricular septal defect, opens from both ventricles. 4)Muscular wall of lower right
ventricle is thicker than normal, called ventricular hypertrophy. Box identifies the defect.
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2.2.1: MORPHOLOGY OF PATHOLOGY
An example a CCHD is hypoplastic left heart syndrome (FIGURE 9: B30),
which is the underdevelopment of the left side of the heart, where 1,025 babies
each year suffer from this CHD in the United States35. Due to the
underdevelopment in the heart it leads to interrupted blood flow in the heart,
mixing the oxygenated and deoxygenated blood, resulting in low levels of oxygen
of the infant. During the first few days of life with hypoplastic left heart syndrome,
the baby’s patent ductus arteriosus and patent foramen ovale may remain open
so the blood can continue to be oxygenated. At the point in which these
alternative routes close, the infants blood oxygen will rapidly decrease, and
surgical intervention is imminent. Even though infants receive surgeries to
alleviate the condition, it is a lifelong debilitation. Children who undergo surgeries
for their hypoplastic left heart syndrome are not cured of the defect. Infants who
are affected by the defect may have life-long complications which would increase
with the complexity of the CHD. Ultimately, if repeated surgeries are needed
and/or the heart weakens, a heart transplant may be the only viable alternative
for the correction of this syndrome36. Coarctation of the aorta (FIGURE 9: C33) is
another CHD that is considered critical, where 4 of 10,000 babies are affected35,
which consists of the narrowing of the aorta. If the narrowed aorta is severe
enough and not diagnosed, the baby may have serious problems and may need
surgical intervention after birth33.
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Another CCHD that requires surgery is the Tetralogy of Fallot due to its
complex defects, CDC estimates that each year 1,660 infants are born in the
United States37. In the Tetralogy of Fallot (FIGURE 9: D34) there are four defects
in the heart which are: 1) A ventricular septal defect, 2) Narrowing of pulmonary
valve and main pulmonary artery, also known as pulmonary stenosis, 3)
Enlarged aortic valve and due to the ventricular septal defect, opens from both
ventricles, and 4) Abnormal thickness of muscular wall of lower right ventricle,
called ventricular hypertrophy15. Surgery after birth is the treatment for this CHD
where surgeons widen or replace the pulmonary valve and enlarge the pathway
of the pulmonary artery. In addition, a patch will be placed to address the
ventricular septal defect. After these interventions occur, the abnormal thickness
of the muscular wall and enlargement of the aortic valve are regulated as there is
less stress in the heart due to the corrections of the defects.
Finally, pulmonary atresia (FIGURE 9: A4) is a CCHD which there is the lack
of development of the pulmonary valve38. The underdevelopment of or absence
of the pulmonary valve disrupts the blood flow of the heart, especially before it is
oxygenated in the lungs. Due to the lack of formation of the pulmonary valve, an
infant’s blood must take other routes to get oxygenated, such as the foramen
ovale4, which is normally closed at when the infant is first born. Pulmonary
atresia may present itself in many variants but is commonly characterized by
whether there is a ventricular septum defect or intact ventricular septum. It is
certain the pediatric patient will need a corrective surgery to treat the pulmonary
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atresia due to their inability to oxygenate their blood in a normal manner, leaving
the infant with lower oxygen levels than are considered healthy. In a 2019 study,
using data from 2010-2014 in the National Birth Defects Prevention Network, it
was estimated that about 550 babies each year in the United States were born
with pulmonary atresia35.

2.2.1.1: MORPHOLOGY OF PATHOLOGY INVOLVING PULMONARY VALVE
ABNORMALITIES
A majority of diagnosed congenital heart defects, 85%, are considered
multifactorial in origin, such as epigenic, environmental, biomechanical, and
hemodynamic factors, to list a few39. Abnormalities to fetal heart development,
explored by Groot et al.39 via different animal models but not yet understood fully,
can then cause an irregular developments of valves of the heart. Such
abnormalities could affect the PV, which could lead to pulmonary atresia in an
infant. In cases of pulmonary atresia, 75% of instances the PV is membranous
while in the remainder of the situations, the PV is muscular. Chubb, et al.38
recognized two groups when the PV is membranous: Lower pressure in the right
ventricle, which is seen in severe tricuspid regurgitation, and prominent
commissural ridges that meet at the center of the thickened PV, and higher
pressure in the right ventricle with less prominent commissural ridges and
smooth thin portions of the PV38. Specifically in pulmonary atresia, the right
ventricle could be effected to either be hypoplastic and hypertrophied38,40 or the

24

right ventricle could be huge dilated, and a thin walled cavity38. What is
consistently seen is a disarrayed myocardium and increased fibrosis38,40.
CCHDs which affect the right ventricular outflow tract (RVOT), such as the
Tetralogy of Fallot, inadvertently have several variations to their morphology.
One variation, particular to the Tetralogy of Fallot, would be the override of the
aortic valve over the ventricular septum defect41. Another observation made by
Khan, et al. 41 is where the orifice and origin of the coronary arteries, which is
abnormal in nature. Coronary arteries present in CCHDs could cross the RVOT
and in these cases when surgical intervention occurs to rectify defects, the
identification of the coronary abnormalities is paramount for the success or
management of the CCHD. Pulmonary valve abnormality, such as pulmonary
stenosis or pulmonary atresia, leads to the RVOT obstruction thus leading to
increased pressure in the right ventricle. As the degree of stenosis increases the
right systolic pressure increases, approximately as a squared function42, in order
to maintain the cardiac output. As a neonatal develops their response to overload
of the right ventricle is compensated by an increased number of capillaries, which
provides the capacity to produce extremely high systolic ventricular pressures42.
Stroke volume in neonates is usually maintained by the hypertrophied muscle,
although sustained elevated pressure for a period of time, cardiac failure could
occur if the ventricle dilated42, but often cardiac output is maintained. These
morphological changes can be seen in a microscopic level through histology.
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2.2.2: HISTOLOGY OF PATHOLOGY
Even though most CCHDs have macroscopic deformities that can be
detected once the heart is looked at, they create alternative morphologies of the
heart as it tries to compensate for the defect. These alternative morphologies are
from the macroscopic level to the microscopic level. Research teams, such as
Groot, et al40,43 and Chowdhury, et al44,45 have analyzed the histopathology of
various heart defects at different stages of a fetus’s development or of a CCHD.
FIGURE 10 shows multiple sections from a 20-week fetus, the fetus has
pulmonary atresia without a ventricular septum, published by Groot, el al40
(Progress in Pediatric Cardiology, 2010). In this case, after birth, doctors would
have to surgically correct the pulmonary valve before the foramen ovale were to
close. Also, due to the pulmonary deformity, there will higher pressure in the right
ventricle to accommodate for the deformity. In FIGURE 10 A, B, and C there is
coronary pathology with intimal thickening and severe adventitial fibrosis in the
subepicardial (SEP) coronary arteries (CA). In FIGURE 10 D the coronary
arteries are severely affected, in the manner of which they are not there. Further
sections were analyzed by Groot, et al43 (Progress in Pediatric Cardiology, 2001)
where ventriculo coronary arterial communications (VCACs) was one of their
main focuses. In FIGURE 10 E and F, the right ventricular wall was of a 20-week
fetus was stained and the intimal thickening of the subepicardial artery was
noted. In addition, in FIGURE 10 F, a more distal section, showed the
abnormality of coronary arteries, where one of them is completely blocked by
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intimal thickening (arrow). FIGURE 10 G and H shows the same specimen as E
and F, with detail view of the wall of the VCAC, which shows no muscular media
(M, in FIGURE 10 G) and the internal elastic lamina of the VCAC on the border
of the intima and destructed media. Demarcation of the side of the ventricular
lumen is shown with an arrow in FIGURE 10 H.
FIGURE 10 I shows the hypoplastic right ventricle of a 5.5-week infant
with pulmonary atresia. In this case, there is extensive endocardial fibroelastosis
(EFE) lining the right ventricle extending to the fibrous tissue that encircles the
hypertrophied cardiomyocytes (M), which is described as a pathological
morphology of CCHDs. Finally, Groot, et al’s group continue to study the
pathologies of CCHDs throughout the development of an embryo. The availability
of such human specimens are highly regulated and in limited supply, thus their
search for an animal model for study. FIGURE 10 J is an example of an animal
model, a chick embryo which was manipulated to inhibit epicardial transformation
and coronary vasculature formation. The histological sections show the right
ventricular apex and the VCAC is marked as well as an abnormal coronary
artery.
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FIGURE 10: Histology from 20-week fetus with Pulmonary Atresia with Intact Ventricular
40

Septum (A-D) . Sections of right ventricular (RV) wall of a 20-week human fetus with
43

pulmonary atresia and ventriculo coronary arterial communications (E-H) . Section of the wall
of a hypoplastic right ventricle of a 5.5-week infant with pulmonary atresia, and myocardial
43

sinusoids (I) . Section through the right ventricular apex of a HH35 chick embryo that was
43

manipulated to inhibit epicardial transformation and coronary vascular formation (J) .
Images taken by Gittenberger-de Groot, et al. Progress in Pediatric Cardiology 29 (2010) 3–9
40

and Gittenberger-de Groot, et al. Progress in Pediatric Cardiology 13, 157-164 (2001)
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Other histological analysis of the pathology of CCHDs have been
published by Chowdhury, et al. in two articles “Histopathology of the right
ventricular outflow tract and the relation to hemodynamics in patients with
repaired tetralogy of Fallot” (J Thorac Cardiovasc Surg, 2019)44 and “Central
pulmonary artery histopathology in patients with cyanotic congenital heart
diseases” (Ann Thorac Surg, 2009)45. FIGURE 11 encapsulates the histology
in these articles. For FIGURE 11 A and C, these were sections taken from a
patient with Tetralogy of Fallot at the point of the Right Ventricular Outflow
Tract. The Hematoxylin and Eosin (H&E) stained sections (FIGURE 11 A and
C) the asterisk indicates myocyte hypertrophy and large hyperchromatic
nuclei (FIGURE 11, C). The patient’s heart has accommodated the abnormal
hemodynamics of the defect, it has affected the cells within the heart and the
RVOT. The other images (FIGURE 11 B and D) show perivascular fibrosis
(indicated with an asterisk) after using Masson’s Trichrome Stain. In this
section is the amount of blue collagen fibers is what accounts for the fibrosis,
as it is in disarray and thicker than what normally would be seen in the RVOT.
Particularly in the FIGURE 11 E and F, Chowdhury, et al. focused on patients
with cyanotic CHDs, thus patients who were not able to keep their oxygen
levels up to par as their body needed and having episodes of oxygen
deprivation. In FIGURE 11 E, the section shows a pulmonary artery biopsy
form a patient with Tetralogy of Fallot which shows a disorganized media with
a loss of smooth muscle cells, and varying grades of mucoid ground
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substance accumulation. Finally FIGURE 11 F is of a patient’s biopsy of their
pulmonary artery undergoing superior cavopulmonary connection, which
shows significant medial destructions, changes in smooth muscle cell
orientation, and intimal thickening. Ultimately the cavopulmonary connection
is coupled with other corrections and surgeries, but it alleviates the patients
cyanotic state even though there are still implications of continuous
abnormalities in the patient’s heart.
All these depictions of histology show that there is a need for ultimate
replacement of vital parts of the heart, so a child does not have continuous
invasive medical treatments, nor does the child ultimately have to have a
heart replacement due to the fundamental damages the defects cause in their
heart.
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FIGURE 11: Histology of the Right Ventricular Outflow Tract biopsy of patients with Tetralogy
44

of Fallot (A-D) . Histology section from pulmonary artery biopsy of a patient with tetralogy of
Fallot shows disorganized media with loss of smooth muscle nuclei and varying grades of
45

mucoid ground substance accumulation(E) . Histology section from pulmonary artery biopsy
of a patient undergoing superior cavopulmonary connection shows significant medial
45

destruction, changes in smooth muscle orientation and intimal thickening(F) . Images taken
from Chowdhury, U.K., et al. J Thorac Cardiovasc Surg 158, 1173-1183 e1175 (2019)
45

Chowdhury, U.K., et al. Ann Thorac Surg 87, 589-596, 596 e581-583 (2009) .
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and

2.2.3: OTHER CHANGES DUE TO CHD
Due to multiple surgeries to correct or alleviate symptoms of CCHDs,
children will continue to need medical attention for the rest of their lives. Also,
surgeries may occur more than once, but if they are done to alleviate symptoms
other problems may occur45 as seen in FIGURE 11 F. As the child who had or
continuous to have defects in their heart, they exercise capacity may be limited47.
If a child had a CCHD that is not common or is more complex to treat, the child
may have developmental delays or other learning difficulties47. Furthermore, it is
imperative to find solutions for children with CCHDs and their families, as the
burden of continuous medical treatment may have social and financial impacts
on all involved47.

2.2.4: CURRENT TREATMENTS
Treatments for CHD, such as tetralogy of Fallot, include the replacement
or alteration of the pulmonary valve (PV), to ensure alleviation of symptoms.
Follow up treatments occur as the child ages due to the lack of adaptability of the
procedures, leading to a cost of $40,385 per life-year gained (2011 US dollars)
until the age of 2048. Current models for replacements, such as mechanical and
biological, have limited life spans due to bleeding risk49 and degradation and/or
calcification50, respectively and do not grow with the patient.
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Current treatments for CHD involving surgery or replacement of the PV do not
consider the children’s change in immunity nor size. An example of CHD is a
child born with a defect in the RVOT, which is a functional unit in the heart that is
located between the supraventricular crest and the PV, such defects include
tetralogy of Fallot and pulmonary atresia51,52. The function of the RVOT is to
carry blood from the right ventricle to the lungs, making the PV a paramount
piece in the process. At the time of diagnosis of defect in the RVOT invasive
surgery is imminent for the child, but current PV replacement options of
xenografts, allografts, and mechanical devices will typically fail and require
another surgery53.
Palliative procedures are considered as an avenue of treatment for most
CCHD cases, as symptoms are the first to be addressed i.e., cyanosis in an
infant. If the palliative procedure is invasive, the surgeon may need to wait to
intervene again54. Such cases can be to address the defect of the PV and other
defects that cause the heart not to distribute non-oxygenated blood and
oxygenated blood in an efficient manner may alleviate symptoms until the next
surgery. Cases have been studied to see whether palliative procedures should
be the first step to management of the CCHDs55, which turns out to be the
manner in most cases but depends on the complexity of the defect. In
Hypoplastic Left Heart Syndrome, a severe CCHD where surgery is imminent for
the infant’s survival. In Hypoplastic Left Syndrome, doctors usually need at least
three surgeries to ultimately correct the underdevelopment of the infant’s heart.
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One of these three surgeries is the Fontan procedure which creates an
alternative pathway for deoxygenated blood to go from the superior vena cava
and the inferior vena cava to the pulmonary artery56. There are continuous
studies of surgical management of various CHDs such as Tetralogy of Fallot57,58
where the claim tends to be that if a corrective surgery is possible then it should
be done, while in more complex cases palliative procedures should be
considered. In addition, there are cases where reconstruction needs to be
considered as it may have been a result of either a surgery or the CHD, one of
which is the reconstruction of occluded pulmonary arteries59. After the procedure,
after 4 years (median of the study) patients returned and received a cardiac
catheterization59. Other follow-ups are seen after care of CCHDs or palliative
care, one of which is pulmonary regurgitation after Tetralogy of Fallot repair60. If
any degree of pulmonary hypertension or pulmonary stenosis occurs, pulmonary
regurgitation is enhanced and right ventricular dilatation is accelerated60.
Ultimately the procedures to treat CCHD are adequate for now, but there is a
need to alleviate their problematic recurrence of treatment for the same defect or
for some other problem that arose from the procedure.

2.2.4.1: PULMONARY VALVE REPLACEMENTS
If a CCHD affect the pulmonary valve and no repair nor reconstruction can
be done, alternatives are considered for pulmonary valve replacements. Most
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commonly used replacements are mechanical prosthetic, or bioprosthetic
valves61. Mechanical prosthesis have thromboembolic risk and lifetime of need
for anticoagulants26, while xenografts and allograft used for right ventricular
outflow tract reconstruction in children and young adults often degenerate and
fail52.
Approximately 85,00 substitute valves are implanted in the United States
each year, where half are mechanical valves and have are bioprosthetic2. Within
15 years following implantation, approximately 50% of porcine aortic valves
suffer tissue failure, thusly although bioprosthetic valves are more attractive for
valve replacements there is a high rate of failure due to structural dysfunction
due to deterioration62-67. Degradation of biological grafts often begins via the
process in which the valve is made, as chemical, mechanical, and morphological
changes occur during manufacturing61. In addition, during fixation of porcine
aortic valve or bovine pericardial tissue leads to destruction of residing cells
which limits their own function to remodel after placement61, and the fixation
locks the collagenous tissue neglecting its function for elasticity in the valve61.
The primary underlying pathologic process is calcification, while secondary is
regurgitation2.
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FIGURE 12: Pictorial hypothetical model for calcification of bioprosthetic tissue. Adapted by
Margarita Bruce from Schoen, FJ and Levy, RJ. Ann Thorac Surg 79 (2005).

Moreover, due to the children’s high immunological competence29, while
surgical approaches to reconstruct valves making use of auto or commercial
available pericardium to augment defective cusps or fabricate mono cusps26
have variable results, as it depends on30,68 but most often fibrosis occurs69.

2.2.4.2: LIFE AFTER CURRENT TREATMENTS
Children with CCHDs that are not relatively complex, may lead normal
lives – if their exercise is limited, and no hypertension nor stenosis occurs47.
Other patients may lead to have more surgeries to ultimately correct their
defects, but with repeated surgeries their hearts might weaken, which may lead
to congestive heart failure. In cases where the child develops congestive heart
failure, a heart transplant is required to save the child’s life70. Now the patient
population that needed to have a PV replacement will have their own plethora of
challenges, such as a mechanical heart valve will lead the child to take a lifetime
36

of anticoagulants and potential recurrence of PV replacement due to the lack of
adaptability of the replaced valve with the growth of the child61. Similar
circumstances of failure can occur with allografts or xenograft valve
replacements due structural degeneration61.

2.3: GAP
Mechanical prosthesis have thromboembolic risk and lifetime of need for
anticoagulants26, while xenografts and allograft used for right ventricular outflow
tract reconstruction in children and young adults often degenerate and fail52. Due
to concerns of the lack of options for children with CHD tissue engineered
constructs continue to be considered if it prevails it can also another approach for
other patients. A tissue engineered pulmonary valve (TEPV) addresses the short
comings of the current methods of valve replacement by creating a living PV.

3: SOLUTION: HEART VALVE TISSUE ENGINEERING
3.1 TISSUE ENGINEERING PARADIGM
As per the notion of tissue engineering, the use of a scaffold, such as a
decellularized porcine pulmonary valve, and autologous cells creates a living
replacement for the organ. The identification of the scaffold, such as a porcine
pulmonary valve, is essential to be comparable to its fresh counterpart. In
addition, the decellularization process removes the potentially immune-rejective
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components, while keeping the structure of the organ. Following the preparation
of the scaffold, autologous cells are embedded into the scaffold and the
combined construct into a conditioning environment (FIGURE 13).

FIGURE 13: Tissue engineering paradigm

The use of a natural scaffold may retain cues which could signal the
patient’s own cells to repopulate the scaffold. In addition, the construct might
adapt to become the patient’s pulmonary valves and regenerate as the child
grows. The regenerative properties of this method could ultimately eliminate the
gap of treatment and the path the way to tailor treatments to the patients.

3.1.1: CELL SOURCE
Concurrently, with the notion of the use of autologous cells the use of human
adipose derived stem cells (hADSCs) as a cell source which are considered for
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the cell population in the tissue construct due to their various advantages of
availability, isolation protocols, and multipotency. The readily availability of
human adipose derived stem cells71,72 and “ability to isolate a consistently
homogeneous population of undifferentiated adult stem cells from adipose
tissue”71 as expressed by Aust, et al makes the source highly desirable. The cells
are also multipotent73,74 as their differentiation properties allow the cells to follow
the path of endothelial cells and smooth muscle cell. The endothelial cell
differentiation, hADSCs are said to have a common progenitor that leads this
differentiation21. The importance of differentiation of hADSCs into endothelial
cells leads to the lining of the scaffold, which will a may ease coagulation and
anticoagulation21 reaction, inflammation, and immune response75.heart

3.1.2: SCAFFOLDS
The use of acellular xenografts as a scaffold follows the tissue engineering
paradigm (TEP). Once the constituents of the TEP of cell and bioreactor are
established, the scaffold is a decellularized material (heart valve, for the purpose
of this project). The decellularization process is followed to remove any antigenic
material that would cause a response from the host76. In this regard, the
decellularized graft is in essence material that does not cause a response from
the host but also a structure which autologous cells will attach and proliferate due
to the “natural environment”. Therefore an acellular xenograft has the
macrostructure for the intended physical position and environment,
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microstructure to induce cell attachment and migration, and molecular structure
in which it has the ability to release molecules to induce specific cell response77.
While autologous cells are isolated and cultured, the acellular scaffold can be
created and with combination of the cells and scaffold a chimeric structure is
created, which ultimately leads to implanting a patient tailored construct78.

3.1.3: BIOREACTOR
Bioreactors further the maturation of the tissue engineered scaffold, in the
manner where they acclimate the construct in a simulated physiological
environment79, such as pH, temperature, pressure, nutrient supply, and waste
removal80. Bioreactors are considered to have at least one of these five
functions, (1) establish uniform cell distribution on a three-dimensional scaffold,
(2) maintain the desired amount of gases and nutrients in the medium, (3)
provide efficient mass transfer to the growing tissue, (4) expose developing
construct to physical stimuli, and (5) provide information of the progress of the
construct with in81. Once the chimeric construct, described previously described,
is developed, the bioreactor will help with the first, second, and third functions, as
Freed, et al. 81 delineated. Physical stimuli mentioned improve the structure and
mechanical properties of the tissue engineered construct82,83. Specifically with
the physical environment being stimulated, such as shear, tension, and
compression84, cells that are seeded on to the heart valve, such as valvular
endothelial cells, could mature and proliferate. This indication of movement of the
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seeded cells is also an important aspect of recognizing that if cells could do that
in a simulated environment the same could happen in an in vivo environment.
Now, even though cell use, scaffold development, and design of bioreactors have
been commonly studied, the method of seeding autologous cells has been an
obstacle that has not yet been standardized nor perfected. Thusly, developments
of instruments to create replicable results are being currently studied/

3.2: CURRENT DEVELOPMENTS IN TISSUE ENGINEERING
3.2.1: 3D BIOPRINTING
An innovation of three-dimensional (3D) printing has emerged, in the
capacity which a combination of cells, growth factors, and biomaterials can now
be used to print 3D structures85. 3D Bioprinting can now fabricate naturally
imitating structures with several bioinks (composition of biological materials that
can be extruded into filament “ink”) into a 3D structure, with crosslinking whether
it be UV photo crosslinking or chemical crosslinking. The method of 3D printing
can replicate designs to small tolerances (depending on the material being used)
and creates porous structures for cells to migrate and communicate with each
other. Due to the computerized nature of the printing, reproducibility, and
increased manufacturing techniques which has been lacking in traditional tissue
engineering methods. The commercialization of 3D bioprinters has also been a
revolution for many niches, such as cardiovascular tissue engineering86. In
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addition, the ability to include gel cell-vehicles has been a something that has
piqued the interest of many researchers87-90. Furthermore, the concept of
reproducibility and controlled manner of cell seeding led to the experimental
design of whether it was better than the traditional manner of seeding for
endothelial cells.
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CHAPTER 2: PROJECT RATIONALE
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AIM 1: CREATE THE FOUNDATIONAL CONSTRUCT FOR A TISSUE
ENGINEERED PULMONARY VALVE
SUB AIM 1: DIFFERENTIATE HUMAN ADIPOSE DERIVED STEM
CELLS INTO ENDOTHELIAL-LIKE CELLS
HYPOTHESIS: Human Adipose Derived stem cells can be differentiated
into Endothelial-like cells with chemical and mechanical stimuli.
APPROACH: Differentiation of ADSCs into ECs will occur when hADSCs
were cultured with Endothelial Cell Growth Supplement (ECGS) media for
up to 3 weeks on 0.1% gelatin coated flasks, then exposed to
physiological shear (12 dynes up to 8 days)91.

SUB AIM 2: DECELLULARIZE A PORCINE PULMONARY VALVE INTO
AN ACELLULAR SCAFFOLD
HYPOTHESIS: A porcine pulmonary valve can be decellularized through a
perfusion system and a change of various solutions.
APPROACH: Porcine pulmonary valves were obtained cleaned and
thinned with a retention of ~5cm of pulmonary artery. Valves were placed
into a metal mounting ring, with an acrylic ring and spring inside. The
valves were placed into a perfusion system and kept at a differential
pressure of 10mmHg (+/- 5 mmHg), with a cyclic regime of 3 minutes ON
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and 30 seconds OFF. For 10 days, the valves were subjected to various
solutions for the decellularization process.

AIM 2: ASSESS THE RETENTION AND ADHESION OF ENDOTHELIAL-LIKE
CELLS ON ACELLULAR VALVE SCAFFOLDS
HYPOTHESIS: A 3D bioprinting seeding method for reendothelialization of an
acellular scaffold will show improved coverage, adhesion and retention of cells as
compared to the drop-wise seeding method.
APPROACH: A pattern of rasterization for emulsion (cells suspended in fibrin)
dispersal will be designed in the 3D bioprinter’s software. Scaffolds would be
prepared into wells of a 6-well plate with a sterilized cotton ball prepared for
further use. For 3D bioprinter cell seeding, the scaffold would be placed “upsidedown”, and the design would be printed, then cotton ball would be placed into the
well and the scaffold would be flipped on to it, final print would happen. For the
manually seeded approach, instead of bioprinting, a syringe would be used to
manually drop-wise seed the scaffold. Several timepoints would be assessed to
show adhesion and retention of cells on scaffold surface. At the time points
seeded scaffold would be analyzed via PrestoBlue assay for quantitative cell
count and Live/Dead for qualitative cell count. Similarly, all the scaffolds at the
time points would be processed for histology with a follow up of
immunohistochemistry to identify the expected presence of cell-cell attachment
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and cell-extra cellular matrix attachment proteins and maintenance of endothelial
markers.

AIM 3: EVALUATE EFFECTS OF DYNAMIC CONDITIONING OF RECELLULARIZED CONSTRUCTS IN A VALVULAR BIOREACTOR
HYPOTHESIS: As the seeded construct is progressively conditioned within the
valvular bioreactor, we expect to prove that seeded cells will maintain adherence,
viability, and specific markers during the conditioning period.
APPROACH: Constructs created in AIM 1 will be mounted in the heart valve
bioreactor to expose the seeded scaffolds to physiological environments. The
assessment of the adhesion and proliferation of cells will be assessed with the
same methodology of AIM 1, as well by finding the expression of endothelial-like
proteins and assessing the endothelial cell like functionality through specific
assays.

EXPECTATIONS AND IMPACT:
By the completion of this project, we expect having developed a biologically
defined biocompatible scaffold seeded with autologous cells, that is potentially
capable of valve regeneration. The approaches and expected results of this
project hold potential for the development of a leading-edge, patient tailored, and
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unique treatment for children with CHD which require pulmonary valve
replacements.
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PART 2: RESEARCH STRATEGY AND INNOVATION
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RESEARCH STRATEGY
SIGNIFICANCE
Cardiovascular disease (CVD) is the prime cause of death nationwide[9],
taking an estimated 17.9 million lives each year[10]. It is speculated that by 2030,
43.9% of the United States population will have some form of CVD26. Under the
umbrella of CVD, more than five millions of Americans are diagnosed with heart
valve disease (HVD) each year27,28. Although most of the population that suffers
from HVD are the elderly, the population of growing children cannot receive the
same treatment as their older counterparts. In the U.S., hospital costs for
individuals with cardiovascular defects in 2013 were about $6.1 billion, where
critical congenital heart defect associated hospitalizations had the highest mean
and median cost of the birth defect categories considered ($79,011 and $29,886,
respectively)29,92.
Events which may lead children to have heart valve defects at birth,
referred to as congenital heart defects (CHD), lead to extensive surgeries
throughout the infant’s life. The American Heart Association estimates that out of
1,000 births at least eight babies will have some sort of CHD in the United
States1,30.
About one in every four babies born with a heart defect has a critical CHD,
identified as heart defects that lead to low levels of oxygen in a newborn, and
will have an invasive intervention with in their first year of life32. The cost of
identifying a newborn with critical CHD has been estimated at $20,862 per
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newborn detected1 and hospitalizations with critical CHD account for 26.7% of all
costs for CHD hospitalization92, where pediatric hospitalizations with CHDs
accounted for approximately $5.6 billion in hospital costs, representing 15.1% of
costs for all pediatric hospitalizations in 200929.
A normal healthy heart is a muscular organ that sits in the chest, and is
composed of four valves, two atriums and two ventricles (FIGURE 14). The
function of the heart is to pump oxygenated blood to the entire body. Infants with
CHD have an improper development of the heart which leads to low level of
oxygen in the newborn. Some CHD can be diagnosed during pregnancy using a
special type of ultrasound, called a fetal echocardiogram, which creates pictures
of the heart of the developing baby. If the defects are not able to be identified
during the pregnancy, they can be identified at birth or as the child ages. Low
levels of oxygen detected with pulse oximetry are the primary identification of a
potential CHD, such as pulmonary atresia (FIGURE 9: A4) hypoplastic left heart
syndrome (FIGURE 9: B36), coarctation of the aorta (FIGURE 9: C33) , and
tetralogy of Fallot (FIGURE 9: D34), detected.
Hypoplastic left heart syndrome (FIGURE 9: B36), is the
underdevelopment of the left side of the heart, which leads to interrupted blood
flow in the heart, mixing the oxygenated and deoxygenated blood, resulting in
low levels of oxygen of the infant. Another CHD is pulmonary atresia (FIGURE 9:
A4), which is the lack of development of a pulmonary valve. The absence of the
pulmonary valve disrupts the blood flow of the heart, especially before it is
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oxygenated in the lungs. A complicated CHD that requires surgery is the
Tetralogy of Fallot due to its complex defects. In the Tetralogy of Fallot (FIGURE
9: D34) there are four defects in the heart which are: 1) A ventricular septal
defect, 2) Narrowing of pulmonary valve and main pulmonary artery, also known
as pulmonary stenosis, 3) Enlarged aortic valve and due to the ventricular septal
defect, opens from both ventricles, and 4) Abnormal thickness of muscular wall of
lower right ventricle, called ventricular hypertrophy.
Treatments for CHD, such as tetralogy of Fallot, include the replacement
or alteration of the pulmonary valve (PV), to ensure alleviation of symptoms.
Follow up treatments occur as the child ages due to the lack of adaptability of the
procedures, leading to a cost of $40,385 per life-year gained (2011 US dollars)
until the age of 201. Current models for replacements, such as mechanical and
biological, have limited life spans due to bleeding risk48 and degradation and/or
calcification49, respectively and do not grow with the patient. Current treatments
for CHD involving surgery or replacement of the PV. do not consider the
children’s change in immunity nor size. An example of CHD is a child born with a
defect in the RVOT, which is a functional unit in the heart that is located between
the supraventricular crest and the PV, such defects include tetralogy of Fallot and
pulmonary atresia50,51. The function of the RVOT is to carry blood from the right
ventricle to the lungs, making the PV a paramount piece in the process. At the
time of diagnosis of defect in the RVOT invasive surgery is imminent for the child,
but current PV replacement options of xenografts, allografts, and mechanical
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devices will typically fail and require another surgery52. Mechanical prosthesis
have thromboembolic risk and lifetime of need for anticoagulants68, while
xenografts and allograft used for right ventricular outflow tract reconstruction in
children and young adults often degeneration and failure26. Degradation of
biological grafts is due to the children’s high immunological competence52, while
surgical approaches to reconstruct valves making use of auto or commercial
available pericardium to augment defective cusps or fabricate mono cusps29
have variable results, as it depends on 26,30,93, but most often fibrosis occurs68.
Due to concerns of the lack of options for children with CHD tissue engineered
constructs continue to be considered if it prevails it can also another approach for
other patients. A tissue engineered pulmonary valve (TEPV) addresses the
short comings of the current methods of valve replacement by creating a living
PV.
As per the notion of tissue engineering, the use of a scaffold, such as a
decellularized porcine pulmonary valve, and autologous cells creates a living
replacement for the organ. The identification of the scaffold, such as a porcine
pulmonary valve, is essential to be comparable to its fresh counterpart. In
addition, the decellularization process removes the potentially immune-rejective
components, while keeping the structure of the organ. Following the preparation
of the scaffold, autologous cells are embedded into the scaffold and the
combined construct into a conditioning environment. The use of a natural scaffold
may retain cues which could signal the patient’s own cells to repopulate the
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scaffold. In addition, the construct might adapt to become the patient’s pulmonary
valves and regenerate as the child grows. The regenerative properties of this
method could ultimately eliminate the gap of treatment and the path the way to
tailor treatments to the patients.
Concurrently, with the notion of the use of autologous cells the use of
human adipose derived stem cells (hADSCs) as a cell source which are
considered for the cell population in the tissue construct due to their various
advantages of availability, isolation protocols, and multipotency. The readily
availability of human adipose derived stem cells69,71 and “ability to isolate a
consistently homogeneous population of undifferentiated adult stem cells from
adipose tissue”72 as expressed by Aust, et al makes the source highly desirable.
The cells are also multipotent71,73 as their differentiation properties allow the cells
to follow the path of endothelial cells and smooth muscle cell. The endothelial cell
differentiation, hADSCs are said to have a common progenitor that leads this
differentiation74. The importance of differentiation of hADSCs into endothelial
cells leads to the lining of the scaffold, which will a may ease coagulation and
anticoagulation21 reaction, inflammation, and immune response21.
The valvular engineering approach follows the tissue engineering
paradigm in which autologous cells are isolated and cultured while
simultaneously creating a scaffold, then creating a chimeric construct which can
implanted into the patient, ultimately implanting the patient tailored construct75.
The need of obtaining such construct is to create a lasting remedy for patients to
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reduce the cost of constituent surgeries. We will keep the structural the unique
micro- and macro- tissue architecture by creating an acellular scaffold with
a pulmonary valve and reendothelialize with autologous cells. The following
project will show a proof of concept with the use of adult pulmonary valve
diameters, average of 23.9mm78, while children’s pulmonary valve diameters
range from 9.2mm – 16.8mm depending on their age of 3 months to 10 years
respectively94.
Key features highlighting the significance of this project are:
•

The great clinical need for a pediatric focused alternative for pulmonary
valve replacement.

•

The tissue paradigm of decellularized pulmonary valve and
reendothelialize with autologous cells.
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INNOVATION
The novelties of the proposed project are the differentiation of hADSCs
into ECs, the use of 3D bioprinting as a method of seeding, and the bioreactor
conditioning of the seeded scaffold. The hADSC-derived ECs are determined by
their expression of EC protein markers through several processes from culturing
to seeding to conditioning on a scaffold. Although differentiation of hADSCs is not
a new concept, their lasting differentiation has not been a focus for research. The
aims proposed are designed to highlight the importance of the endothelialization
of acellular scaffold and focus on the lasting differentiation properties of hADSCs.
Endothelial cell properties and role has been studied at lengths, which will be
considered in the definition of successful differentiated cells. The differentiation
properties of the stem cells are acclaimed in the scientific realm, but their pliable
nature leads to an unconsidered path of their properties as differentiated models.
Under the proposed research methods, the properties of the hADSC-derived
endothelial cells will be monitored within each step of the proposed aims to
ascertain their expressed proteins and their functional role as endothelial cells.
As the tissue engineering paradigm is used, the differentiated cells are to
propagate as their original counterparts should. The use of 3D bioprinting with a
fibrin-cell bioink as a seeding method is also a pioneering notion. The
consideration of the addition of fibrin is for increased attachment of the cells onto
the scaffold, especially when shear force is applied91,95. The added substrate can
increase the retention, specifically within a shear stress environment. Following
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the assessment of manual seeding method in contrast to a 3D bioprinting
seeding, inclusion of bioprinting leads to more consistency and customizability.
Furthermore, progressive bioreactor conditioning of seeded scaffold
generates a living valve with hADSC-derived ECs. Introducing the seeded
scaffold, cells which have been adapted to shear force, to physiological pressure
may yield a living valve. Classifying the importance of the cell adhesion as a full
aim will enable a focus of the adaptability of cells that are retained on the
acellular construct. In addition, there is a consideration of accommodating the
hADSC-derived endothelial cells in their conditioning of pseudo-physiological
environment. Lastly, bioreactor studies with ramp up features of physiological
system has been seen, but not assessed for already shear-conditioned cells.
In summary, innovative features include:
•

The differentiation of hADSCs into endothelial-like cells via chemical and
mechanical stimuli.

•

Endothelization seeding method with 3D bioprinted fibrin-cell bioink

•

Using bioreactor to condition seeded PV to create a living valve.
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PART 3: APPROACH
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AIM 1: CREATE THE FOUNDATIONAL CONSTRUCT FOR A TISSUE
ENGINEERED PULMONARY VALVE
SUB AIM 1: IN-VITRO DIFFERENTIATION OF HUMAN ADIPOSE
DERIVED STEM CELLS (HADSCS) INTO ENDOTHELIAL CELLS VIA
THE ADDITION OF ENDOTHELIAL CELL GROWTH SUPPLEMENT
AND INDUCTION OF SHEAR
METHOD
STEP 1: CULTURE
The differentiation method started with the preparation 0.1% gelatin
solution96 for the pre-coating of the cell culture flasks with the solution via created
via the ATCC protocol97. hADSCs (LaCell, USA) were cultured in Media 199
(Sigma Aldrich, M2154), 13% Fetal Bovine Serum (Bio-techne),
Antibiotic/Antimycotic 12mL/L(Corning), L-glutamine 0.1g/L (Fisher Scientific,
BP379-100), and Heparin 7.5U/mL (Sigma Aldrich, H4784), for 8 days (+/- 3
days). We added Endothelial Cell Growth Supplement (ECGS), 50μg/mL (EMD
Millipore, 02-102) to the medium solution, hADSCs were to be expanded for 3
weeks91. After the addition of ECGS to the medium, it was further referred to as
ECGS media.
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STEP 2: SHEAR
After the differentiation period, the hADSCs were transferred to 6-well
plates (FIGURE 14) and kept in static conditions overnight. Static group
continued to be incubated in same condition, while the shear group was placed
on orbital shaker inside the incubator set to 200 RPM (12 dynes)98. Both groups
grew for an additional 8 days, as per Fischer, et al91 and Dardik, et al98.
Immunofluorescence (IF) was conducted to ascertain the presence of platelet
endothelial cell adhesion molecules (CD31), von Willebrand factor (vWF), and
endothelial nitric oxide synthase (eNOS). Additionally, Acetylated Low Density
Lipoprotein (AcLDL) Uptake assay (ThermoFisher, L3484) was used for the
assessment of the functionality of the differentiated hADSCs into endothelial
cells.
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Figure 14: Visual representation of experimental set up and analysis of wells with their
particular fluorescent assay.

Experimental groups assessed were:
•

Human umbilical vein endothelial cells (hUVECs), referred to as ECs were
plated on a gelatin coated 6-well plates, with media described above
without ECGS. ECs did not experience any shear stimuli.

•

Undifferentiated hADSCs, further referred to as UNDIFF, were plated on
6-well plates without gelatin coating and were cultured with medium
described above without ECGS and heparin. These cells did not
experience any shear stimuli.

•

Differentiated hADSCs were plated on gelatin coated 6-well plates and
cultured with ECGs media, one group experienced shear for 8 days (GEL
SHEAR) and the other was in static conditions for 8 days (GEL STATIC).
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STEP 3: IMAGING
Differentiated hADSCs and control groups, human umbilical vein
endothelial cells (referred to as ECs) and undifferentiated hADSCs (referred to as
UNDIFF), were imaged at various magnifications, 10X, 20X, and 40X analyzed
via ImageJ’s color threshold where the area of the antibody presence (by color of
fluorescence) was identified and normalized by the number of nuclei within the
image. Examples of images and summary of the results are seen in the results.
Several groups, specifically gelatin coated static differentiated hADSCs (GEL
STAT) and gelatin coated shear differentiated hADSCs (GEL SHEAR), were
analyzed and all images were compiled.

STEP 4: IMAGE ANALYSIS
All images were compared, regardless of magnification, which caused
large standard deviations within groups. The area of the fluorescence was
identified by splitting the images into their color channels (Red, blue, and green).
An automatic threshold was applied to the channel of interest, red for AcLDL
Uptake Assay and green for IF protein expression due to the use of
ALEXAFLUOR 488, and by the area was measured using ImageJ. The
“measuring” tool in ImageJ limited the area to the threshold region. A macro was
used to apply the same steps to each image, the results of the area (µm2) and
percentage of area of threshold per image was stored. If the percentage of area
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of the threshold was above 50%, meaning fluorescence took up half of the image
or more, the image was further scrutinized for accuracy. If an inaccuracy was
identified due to the automatic threshold, the data was excluded. The nuclei of
the cells were analyzed via the built-in plugin “Analyze Particle” in ImageJ with
additional steps to clarify the edges of the nuclei. Steps prior to the use of the
“Analyze Particle” were splitting images into the color channels (red, blue, green)
and selecting the blue channel, due the blue fluorescence of DAPI, for further
analysis. The blue channel which includes the DAPI stained nuclei, was made
into a binary image and via the image process of “dilate” to soften the edges of
the particles for ease of identification, and via the image process of “watershed”
was used to segment particles that touched. Finally, the “Analyze Particle” plugin
was used with the limitation of size of 50 µm2-1,000 µm2 to limit the inclusion of
artifacts. A macro was created to include the images scale and steps were
applied to all images. The data was normalized by the number of nuclei and
expressed by the area of protein presence per nuclei of cells (µm2).

RESULTS AND CONCLUSION OF PRELIMINARY SUB AIM 1:
Images were taken to evaluate the AcLDL uptake assay, FIGURE 15
shows representative fluorescent results for the all the groups: EC, GEL SHEAR,
GEL STAT, and UNDIFF.
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Figure 15: Fluorescence images of (A)ECs, (B)GEL SHEAR, (C)GEL STAT, and (D)UNDIFF.
Red fluorescence signifies the uptake of AcLDL, an indicator of a function of endothelial cell.

After analysis of the results of the AcLDL uptake there was no significant
difference between the groups (FIGURE 16), although the differentiated hADSC
in the GEL SHEAR group did show the highest red fluorescent intensity per
nuclei.
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Figure 16: Graphical representation of red fluorescent pixels per nuclei. Quantitative
protocol for AcLDL uptake assay.

ECs expressed the highest intensity, with a statistical difference, of CD31,
eNOS, and vWF compared to the other groups, GEL SHEAR, GEL STAT, and
UNDIFF (FIGURE 18). When the experimental groups were compared to each
other (FIGURE 18), there was a prevalence of higher protein expression in the
GEL SHEAR group, with a significant difference in CD31, when compared to
GEL STAT. Based on the data, UNDIFF group (FIGURE18) showed a decrease
in expression of all proteins, and AcLDL. An example of representative IF images
are seen in FIGURE 17.
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Figure 17: Fluorescence images of endothelial cells (EC, A-C), differentiated hADSCs on a
gelatin coated plate after 8 days of shear (GSH, D-F), and differentiated hADSCs on a gel
coated plate in static conditions (GST, G-I). Green fluorescence identifies the presence of
protein marker shown above the figure.
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Figure 18: Quantification of fluorescent pixels (which indicate protein presence) per nuclei
within the images.

At the culmination of this study, endothelial cell proteins expression was
seen in the experimental groups, supporting the generation of hADSC-derived
endothelial-like cells. Furthermore, differentiated hADSCs up took AcLDL like
their endothelial cell counterparts, further suggesting the similarity in endothelial
functionality between the groups. Finally, the inclusion of shear during the
differentiation process led to more fluorescence, thus increasing the likelihood of
differentiated cells to express more endothelial cell properties. FIGURE 19
summarizes the results of the fluorescence images and their analysis.
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FIGURE 19: Qualitative summary of presence of protein or uptake of AcLDL by each type of
cell. If there was presence and/or uptake of AcLDL it is demonstrated by “+” If there is not a
presence and/or uptake of AcLDL, then by “-“.Furthermore “+/-“ illustrates not a positive
presence nor a negative presence of the protein.

SUB AIM 2: DETERMINATION OF ACELLULARITY OF
DECELLULARIZED PULMONARY VALVE SCAFFOLDS THROUGH
IMMERSION AND PERFUSION.
METHOD:
Two different methods of decellularization were assessed, immersion and
perfusion. During immersion, cleaned and thinned PVs with 5cm< of pulmonary
artery were immersed into various solutions while incubated in a constant state of
motion. As per the perfusion protocol, valves were placed into metal mounting
rings with acrylic rings and a spring inside.
The mounted valves were then plugged in the pulmonary artery opening
then placed into a valve decellularization system, keeping a pressure differential
of 10mmHg +/- 5, in a cyclic regime of 3 minutes ON and 30 seconds OFF. Both
decellularization protocols change through various solutions, such as 0.5M of
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sodium hydroxide (NaOH) [1 hour], detergent solution [4 days, with a change
every two days], 0.02% sodium azide [Rinsing 1 day], DNase/RNase solution [2
days], 70% ethanol [Rinsing overnight], and peracetic acid [2 hours]. The
decellularization process using perfusion apparatus lasted 10 days. During the
final stages of each method, peracetic acid was used to sterilize the acellular
tissue. In the perfusion system extra steps were added to ensure full sterility of
the PV root. For the sterilization of the perfusion system, peracetic acid was
perfused through the system for an hour, following with the disassembly of the
system and valve mounting, finally PVs were moved to a sterile container and
sterility procedure continued until sterile storage. The acellular qualities of the
scaffolds were determined through histology and DNA assays99 to ensure
decellularization procedure by success criteria of (1) no nuclei visible through
histology, via hematoxylin and eosin (H&E) and 4’,6-diamidino-2-phenylindole
(DAPI), (2) the remaining double stranded DNA content did not exceed in 200
base pair in length, and (3) the amount of DNA did not exceed 50ng per mg of
dry weight of the acellular scaffold76,77.

RESULTS AND CONCLUSION OF SUB AIM 2:
The immersion method did not yield acceptable decellularization results
(high residual DNA content, presence of cell nuclei, data not shown). FIGURE
18 shows the change in color of the pulmonary valves after the start of the
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perfusion decellularization process (FIGURE 20 A), and towards the end of the
decellularization process (FIGURE 20 B).

A

B

Figure 20: Images of perfusion decellularization process. A: Image of the pulmonary valves
during the beginning process of decellularization, still pink in color. B: Images of the
pulmonary valves close to the end of the decellularization, white in color indicating
decellularization is successful.

Fresh porcine pulmonary valves were stained with H&E and DAPI at
different positions such as the leaflet/cusp, the sinus pocket, the sinus muscle,
and the proximal pulmonary artery (FIGURE 21). The decellularized PV was also
stained at these positions and compared to the fresh PV.
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A

B

C

D

E F

Figure 21: Location of dissection for the fresh and decellularized pulmonary valve to be
compared to each other.
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Figure 22: Validation of Decellularization of the Pulmonary valve with H&E. A-D: Fresh PV
tissue. Purple indicates the presence of nuclei. E & F: Decellularized PV tissue. No nuclei are
seen in the images. All images are representative of the tissue collected.

Figure 23: Validation of Decellularization of the PV with DAPI. A-D: Fresh PV tissue.
Fluorescent blue indicates the presence of nuclei. E & F: Decellularized PV tissue. No nuclei
are seen in the images. All images are representative of the tissue collected.
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The histology showed the high number of nuclei in the fresh tissue
(FIGURE 22 & 23, A-D), which was mirrored by the gel-electrophoresis (FIGURE
24, LEFT COLUMNS 2-6). The decellularized pulmonary valve, illustrated via
DAPI and H&E, did not have nuclei in prominent regions of muscle and
endothelial layer of the scaffold (FIGURE 22 & 23, E and F).

Figure 24: Validation of Decellularization of the PV with Ethidium Bromide Agarose Gel
Electrophoresis. All columns labeled with their respective sample, LEFT: Standard, MIDDLE:
Fresh, and RIGHT: Decellularized Each decellularized location was sampled twice, thus
each respective locations have two columns in the electrophoresis image.
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Following histology, a gel electrophoresis using 1% agarose gel with
ethidium bromide was conducted with fresh and decellularized samples in the
same run. The gel electrophoresis (FIGURE 24) did not show any DNA based
pairs within the dissected locations shown in FIGURE 21. Each region in the
decellularized valve was ran via two samples, thus two columns, with no
indication of DNA based pairs (FIGURE 24), while the fresh samples illustrated
high DNA based pairs (FIGURE 24).

Figure 25: Validation of Decellularization of the PV with DNA Quantification. Each region was
denoted at the bottom of the graph: (LEFT to RIGHT) Leaflet, Sinus Pocket, Sinus Muscle,
Proximal PV Artery, Muscle 1, and Muscle 2. All locations were compared to a fresh PV
(except for Muscle 1 and 2) and showed a statistical significant decrease from their fresh
counterparts.
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In addition, the DNA quantification of the decellularized pulmonary valve
scaffold and its regions are significantly less that the fresh values (p-value all less
than 0.00) (Graphical representation in FIGURE 25). In addition, all locations
show that there is less than 50 ng of DNA per mg of weight of the tissue, more
samples of decellularized PV muscle were taken and analyze to further prove the
success of decellularization. While comparing the fresh tissue information in
contrast with the decellularized scaffold information demonstrates a statistical
significant difference (FIGURE 25), the decellularized information shows its
satisfactory as an acellular scaffold under the prominent conditions within Crapo,
et al.’s76 considerations. As the conclusion of the preliminary results, using the
perfusion method for decellularization of PV is adequate to create an acellular
scaffold for the replacement of PVs.

CONCLUSION OF AIM 1:
hADSCs showed EC markers after ECGS media was added and shear
stress was induced. In addition, the differentiated hADSCs were able to uptake
AcLDL like their endothelial cell counterparts. Finally, a porcine pulmonary valve
can be decellularized in a perfusion system with several changes of solution.
There were no visible nuclei in the histology (H&E and DAPI), no detectable DNA
base pairs in the Ethidium Bromide Agarose Gel Electrophoresis, and less than
50 ng of DNA per mg of sample. These are the successful definitions of a
decellularized scaffold as per Badylak’s team76.Leading us to conclude that the
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pulmonary valve was successfully decellularized, as any DNA remnants are
deemed insignificant and cannot lead to an adverse reaction if implanted into a
patient99.
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AIM 2 APPROACH: WE WILL COMPARE THE EFFICACY OF TWO CELL
SEEDING METHODS FOR RE-ENDOTHELIALIZATION OF ACELLULAR
VALVES
METHOD:
Decellularized scaffolds from preliminary study will be fitted into 6-well
plates where the valve sits directly into the well (FIGURE 27 B). Valve will be
placed with ventricular side up and the design created using the CELLINK BIOX
3D bioprinter (as shown in FIGURE 28) would be bio-printed onto the valve with
fibrin-cell biological ink.

PRIMARY BIOPRINTING SEEDING STUDY: STATIC CONDITIONS
STEP 1: DEVELOPMENT OF DESIGN TO BE BIOPRINTED
To use the CELLINK BIOX 3D bioprinter for seeding, a design for printing
was developed. A simple design, shown in FIGURE 26 A, was designed via
SolidWorks and was used for the future printing of the fibrin-cell gel construct.
The manner of design was extrapolated from the use of the mounting rings which
are used to place the valves in the bioreactor, and further verified by measuring
the circumference of a decellularized pulmonary valve.
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Figure 26: Design process of the bio-print. A: Design created in Solid Works, diameter of 28
mm and depth of 1 mm, slices were then created to form 3 layers with Slic3r. B: Depiction of
the prints that were going to be placed into a 6 well. C: Image of teach layer and the pattern
in which each layer prints. First layer is on the left and with every added layer the density of
the bio ink increases on the scaffold (Right).

The CELLINK BIOX 3D Bioprinter will print the above design in slices on
decellularized pulmonary valves where the pulmonary artery has been resected
for easier access of the printer’s nozzle onto the valve. As the printer creates the
design of the disk, the nozzle with the fibrin-cell ink will print at a 20.00mm/s and
extrude at a pressure of 20kPa. The profile which the design will be printed is a
hexagonal lattice with a honeycomb infill at a 75% density where the layer height
will be 0.41mm. An example of the design that will be printed is in the figure
above (FIGURE 26 C). The design is further printed into 6-well plates (FIGURE
26 B). An example of the print is shown below, in FIGURE 27, as the CELLINK
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BIOX 3D Bioprinter prints a design with CELLSTARTER ink before moving on to
printing on the decellularized scaffold.

Figure 27: CELLINK BIOX 3D Bioprinter printing example layers with CELLSTATER ink.

STEP 2: PREPERATION OF THE GELMA FIBRIN BIOINK
Prior to printing on decellularized scaffolds, the GelMA FIBRIN bioink was
prepared as per CELLINK’s protocol. In sterile conditions, the GelMA FIBRIN
bioink cartridges were heated up to 37°C for 5 minutes until the bioink became
liquid. Furthermore, differentiated hADSCs were passaged, counted, and then
resuspended into 300µL of a cell suspension with ECGS media. At this point,
CELLINK’s CELLMIXER kit was used with the components given, which were:
1mL syringe, 12mL syringe, dispensing unit, mixing unit, extra bioink cartridge,
female to female Luer lock adapter, and extra printing nozzles. The cell
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suspension was then withdrawn with a 1mL sterile syringe with 20 G needle (to
avoid any more shear damage to the cells as they were going to be printed with a
22 G nozzle). The syringe with cell suspension was placed aside. GelMA FIBRIN
bioink, 3mL, was then transferred to a 12mL syringe, making sure the fibrin was
still liquid. Then the dispensing unit was used by clipping the 1mL syringe with
the cell suspension and 12mL syringe with the bioink, then connecting the
dispensing unit with the mixing unit. The empty cartridge was then placed on the
other side of the mixing unit then compressing the dispensing unit slowly, both
syringe contents were mixed in the mixing unit and the mixture was contained in
the extra bioink cartridge. At this point, the bioink is ready to be printed by the 3D
printed as it will now be called fibrin-cell ink.

STEP 3: PRINTING BIOLOGICAL INK ONTO DECELLULARIZED PULMONARY
VALVES
A sterile cotton ball was be placed into the well and the ventricular side
(VS) of PV was be placed on it, in addition the leaflets were sutured together at
the commissure to ensure no movement of the leaflets occurred nor any leakage
of the fibrin-cell ink. With pulmonary artery side (PS) of the valve on top, the
design was bioprinted, then a photo crosslinking occurred using the 3D Bioprinter
365 nm UV module for 30 seconds. When the bioink was no longer fluid (usually
within 5 – 10 seconds of printing). The same steps were taken with the manual
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drop seeding but the bioprinted design was exchanged with a drop-wise seeding
of a fibrin-cell emulsion. Ultimately two decellularized scaffolds were bioprinted,
two others were manual seeded, and finally a fibrin-cell scaffold was printed.
Finally, a 10 U/mL thrombin solution in ECGS media was placed into the wells,
for further gelation and cleavage of fibrinogen into fibrin. FIIGURE 28 illustrates
the manner in which the valves were placed in 6-well plates.

Figure 28: Experimentally seeded decellularized scaffolds in 6-well plates. Left plate, top:
Scaffold were seeded with bioprinting protocol (BP). Left plate, bottom: Fibrin- embedded
cell printed scaffold (FEC). Right late, top: Scaffolds were seeding with manual-drop wise
procedure. (MAN)

Seeded scaffolds, shown above in FIGURE 26, were then be placed into a
37oC incubator with 5% CO2 to allow for fibrin gelation and culture of cells.
Seeded scaffold were left in static conditions, and analyzed after 24 HRS with
PrestoBlue, then again after 96 HRS. After 4 days, the experiment was finalized
and the scaffolds were examined through Live/Dead assay, and histology of
DAPI and H&E.
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Results of Primary Bioprinting Seeding Study:
After 24 HRs of seeding, PrestoBlue Assay was done to examine the
retention of cells after the initial seeding occurred. This was done by removing
the media in the wells and adding a mixture of 10% PrestoBlue (PB) with media.
This solution was placed into the wells then the plates were placed into 37oC
incubator with 5% CO2, and which were incubated for 10 minutes. After the 10
minutes were up, the PB solution in each well was recovered and replaced with
new media. The plates were placed back into the incubator for further cultivation
of the seeded cells. The PB solution was distributed into an opaque black 96-well
plate and then analyzed for fluorescence using a plate reader, which was set
Excitation/Emission at 560nm/590nm.
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Figure 29: PrestoBlue results of cell retention after 24 HRs of seeding. There was a
statistical difference found in the cell number between manual seeding and bioprinted
scaffold (*) and bioprinted seeding and fibrin-embedded cell print (#), but there was no
statistically significant difference between manual seeding and biopinting seeding, although
more cell retention occurs in bioprinting seeding.

The results of the PB assay after 24 HRS are shown above (FIGURE 29),
where a statistical difference in cell retention is seen between both seeding
methods VS the Fibrin-Embedded Cell scaffold. Although there was no
statistical difference between Manual Seeding and Bioprinted Seeding, there is
a high number of cells counted for Bioprinted Seeding.
Another PrestoBlue assay analysis was done on the final time point of
the experiment, which was 96 HRS/4 DAYS after initial seeding. PrestoBlue
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(FIGURE 30) results demonstrate that there is still a significant difference
between the Manual Seeding and Bioprinted Seeding VS Fibrin-Embedded
Cell scaffold. But in addition to that there was a significant difference in the
number of cells between Manual Seeding and Bioprinted Seeding, 1.9X106
cells VS 1.7 X106 cells, respectively.

Figure 30: PrestoBlue results of cell retention after 96 HRs of seeding. There was a
statistical difference found in the cell number between manual seeding and bioprinting
seeding (%), manual seeding and fibrin-embedded cell print (*), and bioprinted seeding and
fibrin-embedded cell print (#).

In addition to PrestoBlue, the scaffolds were imaged with a stereo
microscope without their sterile cotton ball to identify live cells on scaffolds using
calcein. Each scaffold was then dissected into three parts, into their individual
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leaflets, and preserved in 10% formalin for further histological analysis such as
DAPI and H&E.

Figure 31: Live/Dead stereo scope images of the scaffolds after 4 days in static incubation.
A&D: Manual Seeding, B&E: Bioprinting Seeding, C&F: Fibrin-embedded cell print. All are
representative images of the scaffolds.

Calcein was used to detect where live cells were on the surface of the
valves or fibrin-embedded cell print using a stereo scope. In the manual seeded
scaffold (FIGURE 31 A and D), the cells were able to be seen on the edges of
the fibrin scaffold. In addition, the fibrin gel was seen to have jagged edges off
the scaffold (FIGURE 31 D). As far as the bioprinted scaffold, the cells were seen
on the edges of the leaflets most pertinently (FIGURE 31 B and E), while the
fibrin-embedded cell print did not have obvious cells inside (FIGURE 31 C and
F).
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Figure 32: H&E of scaffolds, 4 days after seeding with manual seeding (A-C), bioprinting
seeding (D-F), and fibrin-embedded cell print (G-I).

In addition, the H&E showed that in both the manual seeded and
bioprinted seeded scaffolds (FIGURE 32 A-C and D-F, respectively), cells were
on the edges of the valve. As the cells that were seeded were differentiated
hADSCs to endothelial-like cells, it demonstrates the beginning of rereendothelialization of the leaflets of the decellularized PV. In the fibrinembedded cell print (FIGURE 32 G-I), it was seen as a condensed gel with
intermittent pores, but no prominent cells were seen.
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SECONDARY BIOPRINTING SEEDING STUDY: DYNAMIC CONDITIONS
STEP 1: PRINTING BIOLOGICAL INK ONTO DECELLULARIZED PULMONARY
VALVES
The design was used from previous study was used, as well as the
method of preparing the fibrin-cell bioink. In contrast from previous procedure,
valves were mounted on polymer rings designed to fit into a rotator cup.

Figure 33: Depiction of bioprinting process. TOP- Step 1: Sterile cotton placed on ventricular
side of PV and flip. Step 2: Print on pulmonary artery side of PV and flip. Step 3: Remove
sterile cotton from PV and print again. BOTTOM- Example of how the fibrin gel stays on the
area it was printed.

Prior to bioprinting seeding a method of step-by-step printing was
established (FIGURE 33 TOP) and an example was created to verify that prints
would stay on their respective side (FIGURE 33 BOTTOM). A sterile cotton ball
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was placed under the ventricular side of the PV and leaflets were sutured
together. Afterwards, the mounted valve (pulmonary artery side up) was placed
into a glass petri dish for bioprinting to occur. Then bioprinter the deposited
emulsion in the manner described in STEP 2 of previous study and then the gel
was photos crosslinked for 30 seconds using the 365 nm UV module. Following
that, using sterile forceps, the mounted valve (now with fibrin-embedded cell gel
on top) was placed upside down in the petri dish and the sterile cotton that was
placed in the ventricular side of the valve was removed. The design created for
the study was printed again, now on the ventricular side of the mounted valve,
and photo crosslinked for 30 seconds using the 365 nm UV module. During each
pause of the bioprinter, a picture was taken with the valve in the petri dish before
printing (FIGURE 34 A), after pulmonary artery side print (FIGURE 34 B), and
after ventricular side print (FIGURE 34 C).

A

B

C

Figure 34: Images of bioprinting process. A: Prior to any bioprinting, B: During bioprinting on
the Pulmonary Artery side of the PV. C: During final print, on the Ventricular Side of the PV.
Blue emulsion is the fibrin-cell bioink
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When the bioprinting was completed on both sides of the decellularized
scaffold, the mounted valves were then placed in rotator cups (FIGURE 35: A)
with media containing 10 U/mL thrombin solution. Two filters were then placed on
the lid of the rotator cups, to allow for gas exchange. Finally, the rotator cups
were placed on to the rotator device (FIGURE 35: B) and set to 1 RPM,
counterclockwise rotation.

Figure 35: Images of valves in the rotator. A) Bottom view of the rotator cups. Movement at 1
RPM, Counterclockwise rotation. B) Top view of the valves in the rotator cup. Movement at 1
RPM, Counterclockwise rotation.

After 24 HRS and 48 HRS the valves were analyzed with PrestoBlue, and
the experiment was finalized. The valves were processed for Live/Dead imaging,
then placed in formalin for further histological study.
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Results of Secondary Bioprinting Seeding Study:
PrestoBlue analysis was done at 24HRs on both valves (n=2) and 48HRs
(n=2) on the same valves as before after seeding and placing the valves in the
rotator. It should be noted, at the time of stop (48HRS) there was some indication
of contamination, thus prior to proceeding the valves were rinsed twice in sterile
DPBS. FIGURE 36 illustrates the results between the time periods, where there
was a significant increase after the 48Hrs of being in the rotator.

Figure 36: PrestoBlue Results between 24 HRS in rotator and 48HRs in rotator, significant
difference between the time points. Indicated by *

In addition to PrestoBlue, both valves were imaged after being incubated
with calcein. FIGURE 37 illustrates the cell distribution among the valves.
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FIGURE 37 A and B shows cells around the leaflets, which FIGURE 37 C shows
cells made it to the rim of the valve, a speculation might be that it was the result
of migration which will further studied in a longer study.

Figure 37: Live images of valves with
bioprinted seeding after 48Hrs of incubation
in the rotator.
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The DAPI illustrated (FIGURE 38) cell accumulation at the edges of the
decellularized PV, leading to the thought of successful reendothelialization of the
PV leaflets.

Figure 38: DAPI of bioprinted scaffolds after 48 HRs in Rotator.
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RESULTS AND CONCLUSION OF AIM 2:
After the primary seeding study, it was seen that cell attachment to the
scaffold was successful. Even though manual seeding showed a significant
increase of cells, bioprinting was further analyzed due to its reproducibility. In the
secondary seeding study, bioprinting seeding was successful in cell attachment,
not only 24HRs after seeding but also after 48HRs. This may have been
contributed to the dynamic nature of rotation, as it allows media movement
through and around the valve. Due to the high number of cell attachment seen in
PrestoBlue and positive results seen of cell attachment not only on the surface of
the valve (seen through the LIVE imaging, FIGURE 37) but transactionally (seen
through the DAPI, FIGURE 38, the next step is to follow the construct and
seeding in a bioreactor with physiological pressures.
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AIM 3: WE WILL CONDITION THE SEEDED SCAFFOLD IN PHYSIOLOGICAL
PRESSURES USING A VALVE BIOREACTOR.
RATIONALE:
The use of valvular bioreactor on a decellularize PV seeded with hADSCderived endothelial cells will condition the construct. Furthermore, the
conditioned construct within the bioreactor will be a proof of concept that the
TEPV would be viable as a PV replacement. In addition, the use of the heart
valve bioreactor will increase the understanding of changes that the environment
induces onto the TEPV. Finally, using the valve bioreactor will produce additional
insight into potential retention and proliferation of cells seeded in the prior aim.

METHODS:
STEP 1: Seeding and introduction to dynamic conditions
When decellularized PV were seeded with hADSC-derived endothelial
cells as the bioprinting seeding method in the previous experiment described.
Both valves were seeded then an analysis of PrestoBlue was done on both
valves for cell counting. Furthermore, after the analysis, the valves were placed
into individual rotator cups and then filled with media (DMEM, 10% FBS, 1%
Ab/Am) and placed into a 37oC incubator with 5% CO2. The rotator was then set
to rotate counterclockwise at 1 RPM for a 24 HR period.
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STEP 2: Heart Valve Bioreactor conditioning with pulmonic pressures.

Figure 39: Proposed timeline for pressure changes throughout bioreactor conditioning.

To achieve the ramp-up suggested in the proposal (FIGURE 39), one
valve was taken to be placed into the Heart Valve Bioreactor (FIGURE 40). The
rotator cup valve was then considered the control, and the valve in the bioreactor
was considered the experimental valve.
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Figure 40: APTUS Heart valve bioreactor for pulmonic
pressures.

Once the valve was mounted into the bioreactor, the bioreactor was then
filled with media (DMEM, 10% FBS, 1% Ab/Am) and placed into a 37oC incubator
with 5% CO2. The PV which was placed into the bioreactor was set to experience
10 mmHg at systolic to 5 mmHg at systolic for 7 days (FIGURE 41 A). Top view
of the pulmonary valve in Heart Valve bioreactor in FIGURE 41 B.
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Figure 41: A) APTUS BIOREACTOR software for heart valve bioreactor, setting of 10 mmHg
systolic pressure and 5mmHg diastolic with 8mmHg differential pressure. B) Image of seeded
PV scaffold in the heart valve bioreactor.

Following the 7th day, both valves were analyzed with PrestoBlue and
Live/Dead. Histology for H&E, DAPI, and Masson’s Trichrome was also done to
assess the location of cells and location of fibrin get. In addition,
immunohistochemistry was done on slides to assess if the endothelial properties
of the differentiated cells were still present.

RESULTS AND CONCLUSION OF AIM 3:
PrestoBlue analysis was done on one valve after seeding, then after 7
days, each valve was analyzed in their respective conditions i.e., bioreactor and
rotator. FIGURE 42 illustrates the cell numbers captivated by the PrestoBlue
analysis. Although it shows there was a significant decrease in cell numbers
between the seeding (n=1) and 7-day conditions (marked by * and $), the valve
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exposed to physiological conditions in the bioreactor (n=1) retained a statistically
significant higher number of cells than the valve in the rotator (n=1), denoted by #
in FIGURE 42.

Figure 42: PrestoBlue analysis done after seeding with the bioprinted and then 7 days under
bioreactor conditions and rotator conditions. There was a statistically significant decrease in
cell number between seeding and the respective conditions, annotated as (*) for bioreactor
and ($) for rotator. But ultimately the bioreactor valve had statistically significant higher cell
count than the rotator (#).

In addition, at the time of disassembly, at 7 days, the valves were imaged
under a stereo scope and analyzed for cell contribution with calcein (FIGURE
43).
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Figure 43: Live imaging of bioreactor valve (A, C, E, G, and I) and the rotator valve (B, D, F,
H, J) after 7 days in respective conditions.
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In FIGURE 43 both valves show a lot of cell attachment on the surface. In
addition, there were cells close to the bottom of sinus of the valve, which was in
the bioreaction, seen in FIGURE 43 I. Each valve was imaged on their pulmonary
artery side (FIGURE 43 A-F) and ventricular side (FIGURE 43 G-I). Although the
Rotator Valve seemed to have more cells, the macroscopic image of the valve
(FIGURE 44) depicted the fibrin-cell gel intact, which after handling fell off.
Images of the fibrin-cell gel that did not fully adhere to the valve, which was
further imaged with DAPI (FIGURE 45, D-E). There was no fibrin-cell gel
substance seen in the bioreactor valve (not pictured).

Figure 44: Macroscopic image of valve after 7 days in rotator, fibrin gel can still be seen on
the leaflets.
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Figure 45: DAPI of Bioreactor Valve (A-C), Fibrin from the rotator valve (D-F) and Rotator
valve (G-I).

DAPI imaging of the bioreactor valve (FIGURE 45 A-C) showed cellular
attachment to the endothelial sides of the valve. FIGURE 45 A shows attachment
of cells on both side of the leaflet. In contrast, there was no continuous cell
attachment on the rotator valve (FIGURE 45 G-I) and the fibrin from the rotator
valve seems to still have cells with in (FIGURE 45 D-F). These images lead us to
believe that the PrestoBlue results of the rotator valve, although their potential
accuracy, overestimated the cell numbers on the valve itself.
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Figure 46: H&E of Bioreactor valve (A-C) and Rotator valve (D-F)

Finally, the H&E results show there are cells on the endothelial layer of the
Bioreactor Valve (FIGURE 46 A-C) and even though similar results seem to be
true for the Rotator Valve (FIGURE 46 D-F), it is not discernable whether the
fibrin has allowed for cells to attach to the valve or if it is the substance attached
to the valve.
In conclusion, AIM 3 was successful in demonstrating that bioprinting a
fibrin-cell gel on valves and conditioning them in dynamic environments keep
cells viable and the fibrin-cell gel keeps the cells on the endothelial side of the
valves. In the Bioreactor Valve, the fibrin-gel was no longer detectable leading to
the conclusion the cells attached to the decellularized valve. In contrast, the
Rotator Valve had obvious signs of the fibrin-gel on the surface with a lot of cells
inside. This leads us to believe that although the delivery vehicle works, in the
rotator the dynamic conditions for 7 days was not able to degrade it, thus no
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conclusion can be made on whether the cell attachment occurred on the
decellularized scaffold in the rotator.

Final Discussion:
Overall AIM 1 and AIM 2 were successful in their findings. In AIM 1, we
were able to find characteristics that apply to endothelial cells after differentiating
hADSCs both with ECGS and furthermore with induced shear. In addition to AIM
1, porcine valves were successfully decellularized and able to be used as
acellular scaffold for the continuation of the TEP. AIM 2 was able to show us the
difference between manual seeding and bioprinting on a scaffold and bioprinting
the scaffold. Although the 3-D printed scaffold by itself did not yield desirable
results, it strengthens the belief that some other type of scaffold (decellularized
PV) was necessary for this junction. In addition, manual seeding and bioprinting
seeding did not show a significant difference in the cell number, but the
reproducibility of bioprinting outweighed the manual seeding. Finally AIM 3
demonstrated that dynamic conditions lead to further cell attachment. Particularly
the valve that was placed into the bioreactor showed that the fibrin-gel delivery
system was successful and its deterioration after the 7 days gives one hope that
the cells have attached and can proliferate with more time.
For further directions on the project, the cell-scaffold construct would have
to be evaluated for longer periods of time. In addition, if this project is used as a
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proof of concept for TEHV for congenital heart defects, next step would be to
downsize the valve. In addition to using a smaller valve, preferably a fetal heart
valve, an animal study would have to be considered. For example, if a fetal
bovine heart is dissected and the pulmonary valve was acquired, after the
decellularization another animal models (such as sheep) cells would be seeded
and then the construct conditioned. After successful conditioning, the newly
seeded and dynamically conditioned fetal construct could be implanted into the
sheep. This would assess whether the TEHV would truly adapt to the animal
model and grow as the model grows.
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